Interlaboratory-concordance of PD-L1 IHC for NSCLC

被引：0

作者：

Scheel, Andreas H.

Banfer, Gudrun

Baretton, Gustavo Bruno

Dietel, Manfred

Diezko, Rolf

Henkel, Thomas

Heukamp, Lukas C.

Jasani, Bharat

Johrens, Korinna

Kirchner, Thomas

Petersen, Iver

Reu, Simone

Schildhaus, Hans-Ulrich

Schirmacher, Peter

Tiemann, Markus

Warth, Arne

Weichert, Wilko

Wolf, Juergen

Ruschoff, Josef

Buettner, Reinhard

机构：

[1] Univ Hosp Cologne, Inst Pathol, Cologne, Germany

[2] Targos Mol Pathol GmbH, Kassel, Germany

[3] Univ Hosp Carl Gustav Carus, Dresden, Germany

[4] Charite, Inst Pathol, Berlin, Germany

[5] TARGOS Mol Pathol GmbH, Kassel, Germany

[6] Haematopathol Hamburg, Hamburg, Germany

[7] NEO New Oncol GmbH, Hamburg, Germany

[8] Charite, Inst Pathol, Campus Berlin Mitte, Berlin, Germany

[9] Univ Munich, Dept Pathol, Munich, Germany

[10] Univ Hosp Jena, Inst Pathol, Jena, Germany

[11] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany

[12] Univ Hosp Gottingen, Inst Pathol, Gottingen, Germany

[13] Heidelberg Univ, Patholog Inst, Heidelberg, Germany

[14] Universitatsklinikum Heidelberg, Dept Pathol, Translat Lung Res Ctr Heidelberg, Heidelberg, Germany

[15] Tech Univ Munich, Inst Pathol, Munich, Germany

[16] Univ Hosp Cologne, Lung Canc Grp Cologne, Ctr Integrated Oncol, Cologne, Germany

[17] Nordhessen & Targos Mol Pathol GmbH, Inst Pathol, Kassel, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.e20508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20508

引用

页数：6

共 50 条

[21] Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer
Prince, Emily
Pratt, James
Novotny, James
Chizhevsky, Vladislav
Ragheb, Josette William
Huron, David
LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 238 - 239
[22] Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer
Prince, Emily
Pratt, James
Novotny, James
Chizhevsky, Vladislav
Ragheb, Josette William
Huron, David
MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 238 - 239
[23] Comparison the results from PD-L1 IHC and PD-L1 multiplex immunofluorescence for the prediction of anti-PD-1 immunotherapeutic response
Sun, Hongzhe
Liu, Xia
Jiao, Tao
Guo, Qian
Du, Haizhen
Han, Shuo
Zhu, Lin
Zhang, Zhifu
Kong, Yan
Li, Na
CANCER RESEARCH, 2024, 84 (06)
[24] Macrophages are important source of PD-L1 and PD-L1 expressing in macrophages affect the prognosis of NSCLC patients with tumor PD-L1 negative
Liu, Y.
Cao, L.
Che, X.
Qiu, X.
Li, Z.
Yang, B.
Wang, S.
Qu, X.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 531 - 532
[25] PD-L1 expression in NSCLC and biopsy size
Kern, I.
Kovacevic, M.
Janzic, U.
Cufer, T.
VIRCHOWS ARCHIV, 2016, 469 : S127 - S127
[26] Radiotherapy and PD-L1 inhibition in metastatic NSCLC
De Ruysscher, Dirk
LANCET ONCOLOGY, 2017, 18 (07): : 840 - 842
[27] A Novel Immunomodulatory Signature Improves Prediction of Response to Immunotherapy Compared to PD-L1 IHC in NSCLC Patients.
Hout, D.
Nielsen, T.
Schweitzer, B.
Seitz, R.
Vidal, G.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S41 - S42
[28] Deep Learning Based Analysis of Multiplex IHC Accurately Interprets PD-L1 and Provides Prognostic Information in NSCLC
Haragan, A.
Nekolla, K.
Kapil, A.
Brieu, N.
Widmaier, M.
Budco, A.
Kanchev, I.
Testori, M. T.
Chan, J.
Schneider, K.
Sastre, A. Hidalgo
Baehner, M.
Schmidt, G.
Field, J.
Davies, M.
Gosney, J.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S203 - S203
[29] PD-L1 and CD8 IHC dual assessment in NSCLC using the Halioseek® assay: A multicentric study
Batista, Luciana
Brandone, Nicolas
Garcia, Stephane
Boumber, Yanis
Dulaimi, Essel
Taniere, Philippe
Hofman, Paul
Ilie, Marius
Adam, Julien
Galon, Jerome
Gerbon, Catherine
Fieschi, Jacques
CANCER RESEARCH, 2018, 78 (13)
[30] A Prospective Study of the Concordance for PD-L1 Status in Core Needle Biopsy and Corresponding Resection Specimen in NSCLC
Lin, D.
Sun, W.
Yang, X.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S777 - S777

← 1 2 3 4 5 →